Skip to main content
Clinical Trials/NCT03956771
NCT03956771
Unknown
Not Applicable

Neurofeedback With Magnetic Resonance Imaging (MRI) for OCD Participants With Treatment-resistance

Pedro Morgado1 site in 1 country30 target enrollmentApril 5, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Obsessive-Compulsive Disorder
Sponsor
Pedro Morgado
Enrollment
30
Locations
1
Primary Endpoint
Mean change from baseline in the score of Perceived Stress Scale with 10 items.
Last Updated
5 years ago

Overview

Brief Summary

The aim of this study is to teach participants with a OCD diagnosis and treatment-resistance how to decrease the response from a brain region involved in the disease by using a technique called neurofeedback. While using this technique, the participants visualize their own brain response in a screen during a MRI exam. Participants will learn strategies to decrease brain responses. The neurofeedback technique is non-invasive, without known risks to participants. With this study, it is expect that the neurofeedback training over 2 weeks (2 sessions) will reduce the OCD symptoms when compared to a control intervention based on neurofeedback's placebo effects.

Detailed Description

OCD individuals will be recruited at Hospital of Braga, Braga, Portugal, in collaboration with the Psychiatry Unit (n = 30, nonrandom convenience sample based on effect size of 0.30, alpha = beta = 0.05, and ANOVA repeated measures within-between interaction). Some participants may quit the study but sample size was predetermined considering a putative 30 percent dropout rate. Clinical history will be assessed (sociodemographic information, disease onset and severity, and previous/current treatments). The participants' neuropsychological state, the blood hormonal levels, and brain function and structure as baseline measures before and after the neurofeedback intervention will be assessed. Two MRI neurofeedback sessions will be performed during 2 weeks (2 distinct days; 36 min per session) in a 3 T MRI scanner. Data analysis will be performed with a repeated measures design (baseline and after neurofeedback) between the groups to measure brain, blood, and neuropsychological changes. Patients will be supervised by a physician to track putative complications/adverse effects during the intervention. The participation will be immediately interrupted in case of adverse reactions or symptomatic worsening and a physician will follow the participants to provide the appropriated care.

Registry
clinicaltrials.gov
Start Date
April 5, 2019
End Date
August 31, 2021
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Pedro Morgado
Responsible Party
Sponsor Investigator
Principal Investigator

Pedro Morgado

Assistant Professor, M.D., Ph.D.

University of Minho

Eligibility Criteria

Inclusion Criteria

  • Primary diagnosis of current OCD according to the fifth Diagnostic and Statistical Manual of Mental Disorders;
  • Treatment resistance (≥ 3 selective serotonin reuptake inhibitors in proper dose for ≥ 12 weeks).

Exclusion Criteria

  • Concomitant psychiatric or neurological illness;
  • Substance abuse/dependence in the past 6 months (except nicotine/caffeine);
  • Acute suicidal ideation;
  • Psychotropic medication (except selective serotonin reuptake inhibitors, anafranil, or low-dose hypnotic or anxiolytic taken occasionally);
  • MRI contraindications (pregnancy, major head trauma, severe claustrophobia, severe back pain, ferromagnetic materials/prostheses/implants inside the body, or other).

Outcomes

Primary Outcomes

Mean change from baseline in the score of Perceived Stress Scale with 10 items.

Time Frame: 2-3 days before the intervention, 2-3 days after the intervention, and 3 months after the intervention.

Psychometric scale to evaluate perceived stress symptoms. The total score ranges from 0 to 40. Lower total scores represent a better outcome.

Mean change from baseline in Emotion Regulation Questionnaire score.

Time Frame: 2-3 days before the intervention, 2-3 days after the intervention, and 3 months after the intervention.

Psychometric scale to evaluate cognitive regulation and emotional suppression capabilities. The cognitive regulation subscale score ranges from 6 to 42 and the emotional suppression subscale score ranges from 4 to 28. Lower emotional suppression scores and higher cognitive regulation scores represent a better outcome.

Mean change from baseline in Hamilton Anxiety Rating Scale score.

Time Frame: 2-3 days before the intervention, 2-3 days after the intervention, and 3 months after the intervention.

Psychometric scale to evaluate anxiety symptoms. The total score ranges from 0 to 56 with the following classification: 0-16 mild anxiety symptoms, 17-24 mild to moderate anxiety symptoms, 25-30 moderate to severe anxiety symptoms, and \>= 31 severe anxiety symptoms. Lower total scores represent a better outcome.

Mean change from baseline in Yale-Brown Obsessive Compulsive Scale score.

Time Frame: 2-3 days before the intervention, 2-3 days after the intervention, and 3 months after the intervention.

Psychometric scale to evaluate obsessive-compulsive symptoms. The total score ranges from 0 to 50 with the following classification: 0-7 sub-clinical symptoms, 8-15 moderate symptoms, 16-31 severe symptoms, and \>= 32 extreme symptoms. This scale can be divided into two subscales: compulsions subscale (score ranging from 0 to 25) and obsessions subscale (score ranging from 0 to 25). The sum of the subscales scores gives the total score of the scale. Lower total and subscale scores represent a better outcome.

Mean change from baseline in Hamilton Depression Rating Scale score.

Time Frame: 2-3 days before the intervention, 2-3 days after the intervention, and 3 months after the intervention.

Psychometric scale to evaluate depression symptoms. The total score ranges from 0 to 52 with the following classification: 0-7 no symptoms, 8-16 mild depression symptoms, 17-23 moderate depression symptoms, and \>= 24 severe depression symptoms. Lower total scores represent a better outcome.

Mean change from baseline in Obsessive-Compulsive Inventory-Revised score.

Time Frame: 2-3 days before the intervention, 2-3 days after the intervention, and 3 months after the intervention.

Psychometric scale to evaluate obsessive-compulsive symptoms. The total score ranges from 0 to 72. This scale can be divided into six subscales: checking subscale (score ranging from 0 to 12), hoarding subscale (score ranging from 0 to 12), neutralizing subscale (score ranging from 0 to 12), obsessing subscale (score ranging from 0 to 12), ordering subscale (score ranging from 0 to 12), and washing subscale (score ranging from 0 to 12). The sum of the subscales scores gives the total score of the scale. Lower total and subscale scores represent a better outcome.

Mean change from baseline in State-Trait Anxiety Inventory score.

Time Frame: 2-3 days before the intervention, 2-3 days after the intervention, and 3 months after the intervention.

Psychometric scale to evaluate anxiety symptoms. The total score ranges from 40 to 160 with the following classification: 40-76 sub-clinical symptoms, \>= 78 clinical symptoms. This scale can be divided into two subscales: state anxiety subscale (score ranging from 20 to 80) and trait anxiety subscale (score ranging from 20 to 80). The sum of the subscales scores gives the total score of the scale. Lower total and subscale scores represent a better outcome.

Secondary Outcomes

  • Differences from baseline in brain grey and white matter structure.(2-3 days before the intervention, 2-3 days after the intervention)
  • Difference from baseline in functional connectivity patterns in the brain.(2-3 days before the intervention, 2-3 days after the intervention)
  • Mean change from baseline in blood hormonal composition(2-3 days before the intervention, 2-3 days after the intervention)

Study Sites (1)

Loading locations...

Similar Trials